CipherBio Weekly Digest: Week of Jan 27 – Feb 2, 2022
This week’s funding events bring $1.77B in deals, $421M in Series A, 40 new companies added to CipherBio. Furthermore, lot of notable announcements in product clinical phases.
New Companies on CipherBio
Top Deals Across Rounds
Septerna raises $100M in Series A round led by Third Rock Ventures. Also in Series A Enable Injections gets $215M led by Magnetar Capital. In Series B Athelas raises $132M led by General Catalyst. Patient 21 raises $142M in Series C round led by Target Global. Alto Pharmacy raises $200M in Series E led by Softbank Vision Fund. Maravai Life Sciences acquires MyChem for $240M. Akili Interactive Labs merger with a SPAC will net it up to $412M.
|Enable Injections||Series A||$215M|
|Patient 21||Series C||$142M|
|Alto Pharmacy||Series E||$200M|
|Maravai Life Sciences||Acquisition||$240M|
|Akili Interactive Labs||SPAC||$412M|
This Week’s Lead Investors in Top Rounds
Products and Clinical Phases
Viracta Therapeutics announces phase 1B/2 trial of Nana-Val in patients with advanced Epstein-Barr virus. Trevi Therapeutics completes enrollment in phase 2B/3 of Haduvio associated with chronic pruritus. Massachusetts-based Viridian Announces announces phase 1 trial of VRDN-002 for the treatment of thyroid eye disease. Arcutis starts their phase 3 trial of topical roflumilast foam in people with seborrheic dermatitis. Reviva Pharmaceuticals begins a phase 3 study of their product Brilaroxazine for the treatment of schizophrenia.
|Company||Product and Clinical Phase||Indications|
|Viracta Therapeutics||Nana-Val, Phase 1B/2||Epstein-Barr Virus, EBV Associated Lymphoma, Solid Tumors, Cancers and Other Neoplasms (NOS)|
|Viridian Announces||VRDN-002, Phase 1||Thyroid Eye Disease, Thyroid Disease, Eye Diseases|
|Aldeyra||Reproxalap, Phase 2||Dry Eye Diseases, Dry Eye|
|Trevi Therapeutics||Haduvio, Phase 2B/3||Pruritus, Peripheral Nervous System, Liver Disease|
|Arcutis Biotherapeutics||Roflumilast, Phase 3||Skin Disease, Seborrheic Dermatitis|
|Reviva||Brilaroxazine, Phase 3||Schizophrenia, Neurological Disorders, Psychiatric Disorders|
|Tracon Pharmaceuticals||TRC102, Phase 2||Lung Cancer, Mesothelioma|
|Aardvark Therapeutics||ARD 101, Phase 2||Metabolic Disorders, Inflammatory Disorders, Prader-Willi Syndrome|
40 Life Science Companies Added
This week we added 40 new life science companies.
|Volta Labs||Susterre Technologies||Yamo Pharmaceuticals|
|Kula Bio||Censys||Iasis Molecular Science|
To get all the latest life science deals and VC funding data delivered straight to your inbox weekly become a CipherBio PRO member.